Zolpimist is unique product for huge market.
No product like that was selling in the market before.
It is much convenient for use, has a faster onset of action characteristics and no food affects.
There are +/- 300,000 USA physicians who can prescribe this product to their clients.
Marketing planers should ask themselves some questions:
1. What is the best way to reach such huge number of physicians to introduce Zolpimist?
2. Is detailing Zolpimist to physician is the best way to cover so many physicians considering ECR with only 45 / 65 marketing force.
3. What are the alternatives available to promote Zolpimist considering 45/65 marketing force?
Management has to think out of the box to maximize the potential of Zolpimist.
Management has to target the potential clients and get their awareness about Zolpimist
advantages. Getting huge number of potential client's awareness can be reached mainly by
media campaigns in a short period compare detailing the product to physicians.
TV, Newspapers & magazines, Internet aids, pharmacies aids etc… combine with detailing
product to physicians should given some excellent results.
Patients should /will call their doctors after seeing/reading the aids of Zolpimist and ask for product prescriptions and not waiting their physician to prescribe the product…
Today when information is more reachable (web / TV shows) marketing should be more divers.
Demand should come from the streets!
I see that, from a recent press release, that nvdl.ob is down to one or two employees. Three directors have resigned. they have stated that they have money only until the end of the month. they have also said that if they find a buyer or funder they will file for bankruptcy protection.
Sorry. This is not good news. for nvdl shareholders or even us, because it confirms that zolpimist sales are not generating enough sales to pay royalties to nvdl (although the amount of sales for royalties to be generated may be high).
You want answers, I'll give you answers (I think that is what Jack Nicolson said).
IMHO (all of the following is my opinion, based upon what I have read from press releases and on this board, or heard on cc's) Zolpimist is a very nice product. It is effective, efficient, convenient, and, speculatively, could be used in at least one alternative way.
It may be a little expensive.
Hitk will not put any money into advertising. It will use its reps, conferences, conventions where they already appear (and other cheap ways). It will not buy superbowl ads, it will not buy other tv or print ads, it will not do info commercials, it will not advertise in the media.
They will simply try to piggy back on the traditional courses they have used in the past. I will add, however, that they appear to have increased their reliance on reps.
I base some of my speculation on naprelin (sp?), which, too, was an excellent product, but which they did not have the means or incentive or insight to pursue.
They are frustrated because they hoped this product would just take off. It will take perssitannce - they will continually push it with reps, hoping that it builds steam. Maybe, just maybe, if it is exceeding $100 million in sales per year they might do an ad or two.
Those are the answers. And you and others posting the same question over and over again will not get you a different answer. Then, again, you might not be able to handle the truth (I know that Jack Nicolson said that).
I add that I've asked questions (where at least one poster got some sales numbers for zolpimist). I did not get answers, but did not feel the need to post question after question after question on the same subject.
I know that you and other nvdl.ob shareholders have not done well. They have come up with a few nice ideas and products, but they have not taken off. But remember this - they have four employees - I speculate that the reason for this company is to pay them salaries - if they run out of money, they just may need to look for other jobs. They do have, at least, a few creditors, which will require payment so that they just can't stick around forever waiting for one of their products to take off.
Good luck. I am still rooting for you. But you wanted answers, so I have repeated the answers I have, and others have, stated in the past.
The problem is that all these "zolpimist junkies" hold nvdl.ob shares, which are in the dumps. They post here hoping that they can drum up some demand, and that they can somehow urge hitk to market zolpimist more aggressively (i.e., buy a SuperBowl ad - yes, a SuperBowl ad - can you believe it - maybe you have a few dollars to spare).
I am just tired of all these zolpimist posts. Yes, it is a good product. Yes, it is a big market for sleeping aides. Yes, hitk certainly touted it in the begining (suggesting that 100m in sales was not out of line), but have failed to deliver so far.
When there are real numbers or a development, we will let all know. Until then, give it a rest.